

Home IV Therapy Outcomes

Self-administration

Injecting Drug Users & OPAT

Pauline Dobson, Dr Mark Loewenthal, Dr Katy Lai Immunology & Infectious Diseases Unit John Hunter Hospital, Newcastle NSW and

Faculty of Health, University of Newcastle



Setting




- Out & About Home IV Therapy Program
- Home IV therapy only, with parenteral antibiotics as majority of admissions
- Infectious Diseases led
- Both paediatric and adult patients
- HITH Clinical database
 - Every admission reviewed by research nurse for completeness of data and problems/complications



HITH Service Coverage HNELHD





Background



- The first HITH started 40 years ago as selfadministered IV antibiotics.¹
 - Still the bulk of this treatment is clinician administered
- Mounting evidence to support self-administration
- Supervised self-administration included in NSW HITH guideline as an approved model of care
- OPAT = outpatient parenteral antibiotic therapy



1. Antoniskis A, Anderson BC, Van Volkinburg EJ, et al: Feasibility of outpatient selfadministration of parenteral antibiotics. West J Med 128:203-206, Mar 1978

What others have found



CrossMark

J Antimicrob Chemother 2016; **71**: 506–512 doi:10.1093/jac/dkv344 Advance Access publication 28 October 2015

Journal of Antimicrobial Chemotherapy

Vascular access complications during outpatient parenteral antimicrobial therapy at home: a retrospective cohort study

Nabin K. Shrestha¹*, Jugnu Shrestha¹, Angela Everett¹, Donald Carroll², Steven M. Gordon¹, Robert S. Butler³ and Susan J. Rehm¹

¹Department of Infectious Diseases, Cleveland Clinic, Cleveland, OH 44195, USA; ²Cleveland Clinic Home Infusion Pharmacy, Cleveland Clinic, Cleveland, OH 44195, USA; ³Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH 44195, USA

Eur J Clin Microbiol Infect Dis (2012) 31:2611–2619 DOI 10.1007/s10096-012-1604-z

ARTICLE

Self-administration of outpatient parenteral antibiotic therapy and risk of catheter-related adverse events: a retrospective cohort study

D. A. Barr · L. Semple · R. A. Seaton

Journal of Antimicrobial Chemotherapy (2007) 60, 356–362 doi:10.1093/jac/dkm210 Advance Access publication 11 June 2007

JAC

Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years

Philippa C. Matthews^{1,2*}, Christopher P. Conlon¹, Anthony R. Berendt^{1,2}, Jill Kayley³, Lorrayne Jefferies⁴, Bridget L. Atkins^{1,2} and Ivor Byren^{1,2}

¹Oxford Radeliffe Hospitals NHS Trust, John Radeliffe Hospital, Headley Way, Oxford OX3 9DU, UK; ²Bone Infection Unit, Nuffield Orthopaedic Centre NHS Trust, Windmill Road, Headington, Oxford OX3 7LD, UK; ³The Pavilion, Thames Road, Goring on Thames, Reading, Berkshire RG8 9AH, UK; ⁴Oxfordshire Primary Care Trust, Unit 1, Isis Business Park, Pony Road, Oxford OX4 2RD, UK



THE NEW ZEALAND MEDICAL JOURNAL Vol 117 No 1200 ISSN 1175 8716

Outpatient parenteral antimicrobial therapy (OPAT): a review of experience at Auckland Hospital

Arlo Upton, Rod Ellis-Pegler, Andrew Woodhouse



Self-administered outpatient parenteral antimicrobial therapy (S-OPAT) for infective endocarditis: A safe and effective model

Marcos Pajarón ^{a,*}, Manuel F. Fernández-Miera ^a, Iciar Allende ^b, Ana M. Arnaiz ^c, Manuel Gutiérrez-Cuadra ^c, Manuel Cobo-Belaustegui ^d, Carlos Armiñanzas ^c, Jose R. de Berrazueta ^e, Maria C. Fariñas ^c, Pedro Sanroma ^a, on behalf of the Hospital Valdecilla Endocarditis Study Group

⁴ Unidad de Hospitalización a Domicilio Hospital Universitario Marqués de Valdecilla, Avda. Valdecilla s/h, 39008 Santander, Spain ⁵ Dept. Medicina de Atención Primaria y Comunitaria, Area de Salal L (J San Fernando 15 Sta. Cruz de Bezana, 39100 Cantabria, Valdecilla s/h, 39008 Santander, Spain ⁶ Dept. Medicina Interna, Unidad de Elformendades Infecciosas, Hospital Universitario Marqués de Valdecilla, Avda ⁶ Dept. Medicina de Valdecilla s/h, 30008 Santander, Spain

International Journal of Infectious Diseases 30 (2015) 161-165



Supervised self-administration of outpatient parenteral antibiotic therapy: a report from a large tertiary hospital in Australia

S. Subedi^{*}, D.F.M. Looke, D.A. McDougall, M.M. Sehu, E.G. Playford Infection Management Service, Princess Alexandra Hospital, Brisbane, Queensland, Australia



Published literature summary



Author (year)	Setting	Journal	Number S-OPAT	Number H-OPAT	Total	Comments
Dobson, Lai,	Out & About IV Therapy Program		2904	4002	6906	OPAT Admissions
Loewenthal 2018	Newcastle Australia	Pending 1637		3157	4794	Patients
Mujal 2016	University Hospital Barcelona, Spain	JAC	351	0	315	Focus on older adults
Strestha 2016	Cleveland Clinic Ohio USA	JAC	1461	0	1461	No comparator group
Subedi 2015	PAH Hospital Brisbane Australia	IJAA	144	0	144	No comparator group
Bhavan 2015	Texas Public hospital USA	PLoS Med	944	224	1168	Uninsured got SOPAT. Propensity score adjusted.
Pajaron 2015	University Hospital Santander, Spain	Eur J Int Med	45	0	45	Infective endocarditis, no comparator
Barr 2012	Glasgow public hospital, UK	IJAA	493	1740	2233	Episodes. Only 1.3% had a PICC
Kieran 2009	St James Hospital Ireland, UK	Eur J CMID	48	12	60	Episodes not patients.
Matthews 2007	Oxford HITH serving 2 hospitals, UK	JAC	513	1621	2134	
Ingram 2007	NUH Singapore	JAC	53	316	369	
Upton 2004	Auckland Hospital, NZ	NZ J Med	94	6	100	
Stiver 1982	Public Hospital Winnipeg, Canada	CMAJ	102	0	102	Used peripheral IVC
Antoniskis 1978	Hospital Portland Oregon, USA	West J Med	13	7	20	First published description


Self-administration Option

- Personal choice
 - Patient / Carer must be willing to self-administer
- Assessed for:
 - Cognition
 - Hygiene
 - Compliance & IDU history
 - Functional
 - Motor skills (dexterity, tremor)
 - Ability to read written instructions (language)
 - Hearing (alarms, telephone contact)
 - Vision (pump controls)



The process

- Teaching session
 - One usually adequate
 - May require more for electronic pumps, or multiple antibiotics



- Extension set, to allow patients to flush PICC using both hands
- Every patient, regardless of whether they are self or clinician administration, are contacted daily by phone
 - Check temp, PICC / pump status, complications, falls



Our Study



- Prospective cohort, paediatric & adult patients admitted to Out & About from 1/10/1995 – 31/12/17
- Only home parenteral <u>antibiotic</u> therapy included
- Clinician administration (H-OPAT)
 - Community nurse, RACF nurse, GP Practice Nurse, HITH nurse in clinic
- Self-administration (S-OPAT)
 - either patient or their carer administers IV therapy



Summary Demographics



Variable	H-OPAT Clinician Administered	S-OPAT Self-Administered	Combined
Admissions	4002	2904	6906
Patients	3023	1771	4794
Patient days	86,968	61,557	148,525
Median Length of stay	21 (1-209)	19 (1-294)	20 (p=0.00001)
Gender – Male	2532 (63.3%)	1690 (58.2%)	4222 (61.1%)
Age – (mean, range)	60.5 (3 months - 96yrs)	40.3 (3 weeks – 92yrs)	51.1
Paediatric	155	449	604



Admissions & Patients

- 81.4% patients admitted once only
- 11.9% had two admissions
- Small numbers of patients have repeated admissions
 - 5.6% had between 4–47 admissions
 - Most are CF and bronchiectasis
- Females have more admissions
 - 1.6 vs males 1.35





			_
Admissio Per patie	Number of Patients		Percent
1	3902		81.4
2	573		11.9
3	149		3.1
4	57		1.19
5	25		0.52
6	18		0.38
7	10		0.21
8	9		0.19
9	5		0.10
10	9		0.19
11	6		0.13
12	4		0.08
13	3		0.06
14	2		0.04
15	7		0.15
16	1		0.02
18	2		0.04
19	2		0.04
20	2		0.04
21	1		0.02
23	1		0.02
25	1		0.02
30	1		0.02
31	1		0.02
35	1		0.02
45	1		0.02
47	1		0.02
Total	4794		100

Conditions Managed by Admission

Variable	Clinician (n=4002)	Self (n=2904)	Combined (n=6906)
Bone & Joint infection	2330 (58.2%)	1263 (43.5%)	3593 (51.8%)
Cystic Fibrosis	82 (2%)	794 (27.3%)	876 (12.7%)
Abscess	296 (7.4%)	165 (5.7%)	461 (6.7%)
Skin & Soft Tissue	287 (7.2%)	132 (4.5%)	419 (6.1%)
Infective endorcarditis	315 (7.9%)	93 (3.2%)	408 (5.9%)
Sepsis/Bacteraemia	251 (6.3%)	127 (4.4%)	378 (5.5%)
Bronchiectasis/COPD	147 (3.7%)	128 (4.4%)	275 (3.9%)
Other Infection	294 (7.3%)	202 (6.9%)	496 (7.2%)



Other infection includes: malignant otitis media; encephalitis; ascending cholangitis; empyema; nocardia; meningitis; parotitis; leptospirosis; pyomyositis; pericarditis, infected devices e.g. pacemakers, permacaths, CVCs, cochlear implants, VP shunts, peritoneal dialysis catheters; abdominal mesh

What type of line did they have?

N
Y

Vascular Device	Clinician	Self	Combined
PICC	3807 (92.1%)	2329 (78.1%)	6136 <mark>(86.2%)</mark>
Implantable Port	91 (2.2%)	566 (18.9%)	657 <mark>(9.2%)</mark>
сус	202 (4.9%)	66 (2.2%)	268 <mark>(3.8%)</mark>
Tunnelled Catheter	34 (0.8%)	21 (0.65%)	55 <mark>(0.8%)</mark>
Total	4134	2982	7116


More catheters than patients, some required 2nd catheter to finish course




Mode of parenteral antibiotics



Mode	Clinician	Self	Total
Continuous 24h	3856 (90.5%)	2582 (75.1%)	6438 (83.6%)
Bolus	313 (7.4%)	717 (20.8%)	1030 (13.4%)
Intermittent infusion	90 (2.1%)	141 (4.1%)	231 (3%)
Total	4259	3440	7699




Age by who administered






Proportion self-administering over time

 The proportion of those who self-administer has now plateaued




 And remains the case when Cystic Fibrosis is excluded





Were they discharged early or readmitted?





Lines

Vorun		
Line Days	Failures	Failure Rate per 1000 line days
86,421	291	3.4

Total	7117 (147,722	453	3.1
Self S-OPAT	2983	61,301	162	2.6
Clinician H-OPAT	4134	86,421	291	3.4
	Linco	Line Days	i ultiti oo	1000 line days


Equivalent > 400 patient years of follow-up



Administration


Line Survival by Who Administers







All line complications



20 of 37

0

7

--- H-OPAT

0.04

0.03

0.02

0.01

0.00

0.04

0.03

0.02

0.01

0.00

0

7

Pros and Cons of Self-Administration




- Self-administration survey of Out & About Patients
 - Advantages
 - "not tied down (to time when it suits nurse to call)"; "control over situation" "family life normal", "get back to work", "helps understanding of disease"
 - Choose self-administration again: 93%
- Service Advantages
 - Suitable for rural areas where limited numbers of nursing staff working 7 days / week & evenings
 - Capacity of service is not as affected by number of HITH team staff
 - Costs lower: fewer staff, cars & transport
- Service Disadvantages
 - Requires thorough assessment prior to acceptance





 In selected patients, self-administration is safe, and equivalent or better in outcomes to clinician administered home parenteral antibiotic therapy







GEREN DURE D'AITEEURI TAGO KIO GEMODTUO

Introduction



 In a recent report, 30% of IDU being treated for infection and discharged on oral antibiotics left hospital against medical advice²



Comparing IDU & Non-IDU



- Examined all admissions to home IV antibiotic program, compared outcomes in IDU/non-IDU
- Created "last used" classification (self report / questioning)
 - Current: used within the last 3 months
 - Recent: used 4 months to 2 years
 - Distant: used more than 2 years ago
- CDC criteria for Laboratory confirmed blood stream infection (LCBI)
- Non-compliance recorded in problem record e.g.
 - Not available when community nurse visits, uncontactable for daily phone calls, missing medical review appointments, refusing to come in to the clinic when problems arise



Demographics



- 1995 2017 (1st IDU admission 1998)
- Non-IDU 6,493 admissions
- IDU 162 admissions in 122 patients (range 1-11 admissions) 159 evaluable
 - Non-IDU 61% Male; IDU **70% Male** *p*=0.026
- Days on HITH program
 Non-IDU 134,909 days, median 20 days
 IDU 3,502 days, median 23 days p=0.013



IDU Conditions treated

- Bone & Joint Infection (51.8%)
 - Native bone & joint infection 64, (39.5%)
 - Prosthetic bone & joint 20 (12.3%)
- Endocarditis 35 (21.6%)
- Bacteraemia 18 (11.1%)
- Abscess 12 (7.4%)
- Skin & Soft tissue 4 (2.5%)
- Other (5.5%): mycotic aneurysm, infected cranioplasty, empyema, neurosyphilis, pneumonia, infected cardiac prosthesis (pacemaker leads)






- Peripherally inserted central catheters PICCs = 141 (88.7%)
- Subclavian CVC = 15 (9.4%)
- Implantable port = 3 (1.9%)

Reflection of access difficulties







Median age

• IDU = 41.5 years; Non-IDU 56.8 years *P*=0.009



- Current (in last 3 months) = 57 (35.8%)
- Recent (4 months 2 years) = 25 (15.7%)
- Distant (more than 2 years) = 67 (42.1%)

• Unknown / Not documented = 10 (6.3%)





- Non compliance events:
 - Non-IDU 38, **0.61%** IDU 10, **6.4%** *p*=<0.001

Compared to non-IDU

- Current IDU are 16.4 x more likely to be noncompliant (95% CI 6.2 – 43.4) p=<0.001
- Recent IDU are 14.3 times more likely to be noncompliant (95% CI 3.25-62.63) p=<0.001
- Distant IDU are 7.69 x more likely to be noncompliant (95% CI 2.3 – 25.55) p=0.001





Measure	Non-IDU (n=6493)	IDU (n=159)	P value
Early discharge (complication)	143 (2.2%)	2 (1.3%)	0.32
Readmission	169 (2.6%)	1 (0.6%)	0.08
After hours phone call use	1021 (15.8%)	29 (18.3%)	0.22
After hours call out	240 (3.7%)	14 (8.9%)	0.003



Catheter complications

- All catheter complications
 - IDU 4.8/1000 catheter days
 - Non-IDU 3.4/1000 catheter days *p*=0.31


Incidence rate compared

Catheter complication	Non-IDU (Events, IR)	IDU (Events, IR, p value)
Blockage	93 events; IR 0.69	4 events; IR 1.1, p=0.42
Phlebitis	56 events; IR 0.42	1 event; IR 0.29, p =0.76
Catheter damage	65 events; IR 0.48	3 events; IR 0.85, p=0.36
Thrombosis	33 events; IR 0.24	0 events; IR 0, p=0.34
Accidental Removal	23 events; IR 0.17	3 events; IR 0.86, p=0.003
Definite line infection	4 events; IR 0.029	0 events; IR 0, p=0.72



Catheter Survival





Hunter New England

Health

34 of 37

Hazard Ratio – Line failure

- Current
 ▶2.4 (95% CI 1.23-4.64, *p*=0.01)
- Recent
 ≻0.39 (95% CI 0.56 2.83, *p*=0.36)
- Distant
 - ≻1.03 (95% CI 0.46 2.32, p=0.93)
- Unknown

≻1.02 (95% CI 0.14 – 7.28, *p*=0.98)

Hazard Ratio is the risk of a negative outcome (line failure) in one group (non-IDU) compared to another group (IDU) occurring at a given point in time





Long term success



- Criteria determined at time of admission
- 6 months after discharge patients are contacted to see if they have met the predetermined success criteria
 - e.g. no recurrence of infection, no readmission for same condition, off antibiotics, functional joint, wound healed, alive
- Non-IDU 80.5% long term success
- IDU 78% long term success (p=0.6)









- In our cohort of selected IDU patients
 - Catheter damage, blockage, and accidental removal are more frequent in IDU but only accidental removal is statistically significant
 - Non-IDU are more likely to be discharged early or be readmitted than IDU
 - Non-compliance with therapy is much more likely in IDU
 - Selected IDU can be managed appropriately on HITH and have similar outcomes to non-IDU (98% complete their course)
 - Thorough assessment that includes compliance and behaviour in the inpatient setting is essential before accepting an IDU on HITH

